Table 3. Comparison of Normalized Bending Rigidity Values of Phospholipid Vesicles in the Fluid Phase with Various Small Drug Molecules as a Function of the Molar Percentage of the Drugs in Respective Lipid Membranes.
| drug | lipid and conditions | molar % drug | method | normalized bending rigidity
|
reference | |
|---|---|---|---|---|---|---|
| no drugs | DOPC, LUV | 0 | NSE-multiplicative model | 1 | this work | |
| Acetaminophen | DOPC, LUV | 25 | NSE-multiplicative model | 0.6 | this work | |
| Acetaminophen | DOPC, LUV | 37.5 | NSE-multiplicative model | 0.53 | this work | |
| Ibuprofen | DMPC | 25 | NSE-ZG model | 0.67 | (59) | |
| Indomethacin | DMPC | 25 | NSE-ZG model | 0.61 | (59) | |
| Aspirin | DMPC | 25 | NSE-ZG model | 0.81 | (59) | |
| Aspirin | DMPC | 36 | NSE-ZG model | 0.67 | (60) | |
| Salicylate | SOPC, GUVs | N/A (1 mM) | micropipette aspiration and dynamic tension spectroscopy | 0.67 | (19) | |
| Ibuprofen | DMPC (pH < 2), SUV | 30 | NSE-ZG model | 0.67 | (20) | |
| Ibuprofen | DMPC (pH > 2), SUV | 30 | 0.47 | (20) |
